---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-043322"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2024-11-01T23:59:59+00:00"
generated_at: "2026-05-30T06:56:41.954066+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BriaPro sub of BriaCell reports $420K net loss, going concern uncertainty

## Summary
- BriaPro incurred net loss of $420,287 for year ended July 31, 2024; accumulated deficit $440,209 since incorporation in May 2023.
- Total assets $199,797; current liabilities $455,650; shareholders' deficit $405,694; cash balance $1.
- Auditor's report includes material uncertainty paragraph about going concern; company is pre-clinical with no commercial operations.
- Intangible assets (patents) of $199,796 acquired from BriaCell via spinout arrangement on August 31, 2023.
- BriaCell beneficially owns 2/3 of BriaPro's outstanding common shares (31,963,452 of 47,945,178 shares).

## SEC filing metadata
- accession: 0001493152-24-043322
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2024-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315224043322/0001493152-24-043322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315224043322/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-043322
- JSON: https://secwatch.observer/filing/0001493152-24-043322.json
- Plain text: https://secwatch.observer/filing/0001493152-24-043322.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.